A single infusion of VERVE-102 reduced LDL cholesterol by up to 62% in early trials. Here's what the latest cholesterol ...

As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions ...

Please provide your email address to receive an email when new articles are posted on . In patients with atherosclerosis or diabetes who had PCI but no prior heart attack or stroke, evolocumab reduced ...

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing proposals in the US. When low-price foreign markets become linked to large U.S ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its newer products will offset the loss of revenue from patent expirations and ...

Yes, Repatha is still available as a medication used to help lower “bad” LDL cholesterol and reduce the risk of serious heart problems. However, while the medication itself is still available, the way ...

Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

The primary difference between the Wegovy pill and the injection is how you take them and how often. The Wegovy pill is a daily tablet you swallow, while the Wegovy injection is a once-weekly shot you ...

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?

Merck said it plans to share enlicitide data from three trials with regulatory authorities worldwide. (Photo by Kena Betancur/Getty Images) In late-stage studies, Merck & Co.’s PCSK9-targeted pill ...